Genezen, a gene therapy CDMO, has agreed to acquire uniQure’s commercial gene therapy operations in Lexington, MA, bringing a strategic manufacturing facility and an experienced team of employees to the company. Under the terms of the agreement, Genezen will enter into strategic supply agreements for uniQure’s clinical portfolio and CSL’s commercial HEMGENIX product, the first one-time gene therapy approved in the U.S. and Europe for the treatment of adults with severe and ...